"We intend to conduct scientific research on the relation between cannabis and Covid"

THC BioMed has been granted a license by an overseas government to cultivate cannabis for medical and scientific use.

"We are in advanced discussions with the host government to conduct Scientific Research with Cannabis. We intend to conduct scientific research and development on whether Cannabidiol ("CBD") and other compounds from the cannabis plant have the potential to prevent or inhibit SARS-CoV-2 infection."

"We are interested in researching and studying cannabis compounds and their potential effects on SARS-CoV-2 infection. Since March 2020, we have been looking into the possibilities and challenges of carrying out an R&D program in relation to cannabis and SARS-CoV-2. Other scientific research regarding cannabis is also of interest to us. We have made inquiries with different governments regarding licences to conduct cannabis research and development. We are currently in advanced talks with the host government and received, on January 19, 2022, a licence for the production of cannabis for medical and scientific use."

"We are now seeking amendments or clarification on our new licence regarding whether additional permission is required for the conduct of our planned scientific testing. There is no guarantee that the research and development we intend to conduct will be allowed under the current licence or that a further licence for research and development, if needed, will be granted to us."

For more information:
THC BioMed

Publication date:

Receive the daily newsletter in your email for free | Click here

Other news in this sector:

Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber